comparemela.com

Latest Breaking News On - Arqule inc - Page 3 : comparemela.com

Press Release: Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and lisavanbulin at AACR Annual Meeting

Basel, Switzerland, April 13, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer

Basel stadtUnited statesM el shemerlyF bertoni avanbulinLaurenz kellenbergerP mcsheehy derazantinibMerck co incBertoni institute of oncology researchArqule incBasilea pharmaceutica ltdPress releaseAnnual meetingAmerican associationCancer researchNew orleansChief scientific officer

Basilea Pharmaceutica AG: Basilea to become a leading anti-infectives company backed by strong financial results 2021

65% year-on-year growth in non-deferred revenue from Cresemba and Zevtera Operating profit of CHF 1.2 million Future strategic focus on anti-infectives Exploring strategic options to maximize the value

United statesBasel stadtNils schrAsahi kasei pharmaDavid veitchNicole onettoThomas wernerDomenico scalaCresemba zevteraMartin nicklassonLeonard kruimerAdesh kaulStevend skolskyHead of corporate communications investor relationsArqule incMerck co inc

Drug Discovery Technologies Market SWOT Analysis by Leading Key Players: Novartis, Bayer Healthcare, GE Healthcare

Drug Discovery Technologies Market SWOT Analysis by Leading Key Players: Novartis, Bayer Healthcare, GE Healthcare

United statesUnited kingdomCzech republicSri lankaNew zealandSouth koreaRepublic ofSouth africaSaudi arabiaCustom researchAgilent technologies incAbbott laboratories incArqule incDetailed company profiles of key emerging playersMarket intelligence consulting privateAlbany molecular research inc

Drug Discovery Technologies Market SWOT Analysis by Leading Key Players: Novartis, Bayer Healthcare, GE Healthcare

Drug Discovery Technologies Market SWOT Analysis by Leading Key Players: Novartis, Bayer Healthcare, GE Healthcare

United statesUnited kingdomCzech republicSri lankaNew zealandSouth koreaRepublic ofSouth africaSaudi arabiaCustom researchAgilent technologies incAbbott laboratories incArqule incDetailed company profiles of key emerging playersMarket intelligence consulting privateAlbany molecular research inc

Basilea Pharmaceutica AG: Basilea presents preclinical data on synergy between derazantinib and paclitaxel in gastric tumor models at ANE Conference

Basel, Switzerland, October 11, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the presentation of data from preclinical studies demonstrating synergistic anti-tumor effects in a number

Basel stadtUnited statesUnited kingdomNils schrLaurenz kellenbergerHead of corporate communications investor relationsArqule incSwiss exchangeBasilea pharmaceutica ltdVirtual international conference on molecularCancer researchMerck co incClinical cancer researchVirtual international conferenceMolecular targetsCancer therapeutics

vimarsana © 2020. All Rights Reserved.